• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

相似文献

1
Prognosis of esophageal squamous cell carcinoma patients with preoperative radiotherapy: Comparison of different cancer staging systems.术前放疗的食管鳞癌患者预后:不同癌症分期系统的比较。
Thorac Cancer. 2014 May;5(3):204-10. doi: 10.1111/1759-7714.12079. Epub 2014 Apr 22.
2
Comparison of the 6th and 7th editions of the American Joint Committee on Cancer tumor-node-metastasis staging system in patients with resected esophageal carcinoma.比较第 6 版和第 7 版美国癌症联合委员会肿瘤-淋巴结-转移分期系统在食管癌切除患者中的应用。
Ann Thorac Surg. 2010 Apr;89(4):1024-31. doi: 10.1016/j.athoracsur.2010.01.017.
3
Proposed Modification of Nodal Staging as an Alternative to the Seventh Edition of the American Joint Committee on Cancer Tumor-Node-Metastasis Staging System Improves the Prognostic Prediction in the Resected Esophageal Squamous-Cell Carcinoma.提出的淋巴结分期修改方案作为美国癌症联合委员会肿瘤-淋巴结-转移分期系统第七版的替代方案,可以改善可切除食管鳞癌的预后预测。
J Thorac Oncol. 2015 Jul;10(7):1091-8. doi: 10.1097/JTO.0000000000000580.
4
[Evaluation of the value of 7th editions of UICC-AJCC esophageal and gastric cancer TNM staging systems for prognostic prediction of adenocarcinoma of esophagogastric junction (Siewert type II)].[UICC-AJCC第7版食管癌和胃癌TNM分期系统对食管胃交界腺癌(SiewertⅡ型)预后预测价值的评估]
Zhonghua Zhong Liu Za Zhi. 2014 Dec 23;36(12):916-21. doi: 10.3760/cma.j.issn.0253-3766.2014.12.008.
5
Comparison of the 6th and 7th editions of the AJCC/UICC TNM staging system for gastric cancer focusing on the "N" parameter-related survival: the monoinstitutional NodUs Italian study.聚焦于“N”参数相关生存率的AJCC/UICC胃癌TNM分期系统第6版与第7版比较:意大利单中心NodUs研究
World J Surg Oncol. 2015 Jul 16;13:215. doi: 10.1186/s12957-015-0633-3.
6
Proposal and validation of a modified staging system to improve the prognosis predictive performance of the 8th AJCC/UICC pTNM staging system for gastric adenocarcinoma: a multicenter study with external validation.提出并验证了一种改良的分期系统,以提高第 8 版 AJCC/UICC pTNM 分期系统对胃腺癌预后预测性能:一项多中心研究及外部验证。
Cancer Commun (Lond). 2018 Nov 19;38(1):67. doi: 10.1186/s40880-018-0337-5.
7
A comparison between the sixth and seventh editions of the UICC/AJCC staging system for nasopharyngeal carcinoma in a Chinese cohort.中国队列中 UICC/AJCC 鼻咽癌分期系统第六版与第七版的比较。
PLoS One. 2014 Dec 23;9(12):e116261. doi: 10.1371/journal.pone.0116261. eCollection 2014.
8
Comparison of the 6th and 7th Editions of the UICC-AJCC TNM Classification for Esophageal Cancer.UICC-AJCC TNM 分期系统第 6 版与第 7 版比较——食管癌
Ann Surg Oncol. 2012 Jul;19(7):2142-8. doi: 10.1245/s10434-012-2218-5. Epub 2012 Mar 7.
9
A comparison of the 7th and 8th editions of the AJCC staging system in terms of predicting recurrence and survival in patients with papillary thyroid carcinoma.第 7 版和第 8 版 AJCC 分期系统在预测甲状腺乳头状癌患者复发和生存方面的比较。
Oral Oncol. 2018 Dec;87:158-164. doi: 10.1016/j.oraloncology.2018.11.003. Epub 2018 Nov 9.
10
Comparison of 6th and 7th AJCC TNM staging classification for carcinoma of the stomach in China.中国胃癌第 6 版与第 7 版 AJCC TNM 分期比较。
Ann Surg Oncol. 2011 Jul;18(7):1869-76. doi: 10.1245/s10434-010-1542-x. Epub 2011 Jan 19.

引用本文的文献

1
KLF13 promotes esophageal cancer progression and regulates triacylglyceride and free fatty acid metabolism through GPIHBP1.KLF13通过GPIHBP1促进食管癌进展并调节甘油三酯和游离脂肪酸代谢。
Cell Death Dis. 2025 May 31;16(1):425. doi: 10.1038/s41419-025-07709-7.
2
Comparison of the Oncologic Outcomes for Patients with Middle to Lower Esophageal Squamous Cell Carcinoma Undergoing Surgical Treatment Using the Ivor-Lewis or McKeown Operation.比较经 Ivor-Lewis 或 McKeown 手术治疗的中下段食管鳞癌患者的肿瘤学结局。
Ann Surg Oncol. 2024 Nov;31(12):7750-7758. doi: 10.1245/s10434-024-15888-4. Epub 2024 Jul 27.
3
The Gum-Gut Axis: Periodontitis and the Risk of Gastrointestinal Cancers.牙龈-肠道轴:牙周炎与胃肠道癌症风险
Cancers (Basel). 2023 Sep 15;15(18):4594. doi: 10.3390/cancers15184594.
4
Applying post-neoadjuvant pathologic stage as prognostic tool in esophageal squamous cell carcinoma.将新辅助治疗后的病理分期作为食管鳞状细胞癌的预后工具。
Front Oncol. 2022 Nov 10;12:998238. doi: 10.3389/fonc.2022.998238. eCollection 2022.
5
The staging performance of a modified tumor-node-metastasis staging system incorporated with lymphovascular invasion in patients with esophageal squamous cell carcinoma.改良的肿瘤-淋巴结-转移分期系统结合淋巴管侵犯在食管鳞状细胞癌患者中的分期表现。
Front Oncol. 2022 Oct 13;12:1018827. doi: 10.3389/fonc.2022.1018827. eCollection 2022.
6
Epiplakin1 promotes the progression of esophageal squamous cell carcinoma by activating the PI3K-AKT signaling pathway.Epiplakin1 通过激活 PI3K-AKT 信号通路促进食管鳞状细胞癌的进展。
Thorac Cancer. 2022 Apr;13(8):1117-1125. doi: 10.1111/1759-7714.14366. Epub 2022 Mar 3.
7
Prognostic effect of perineural invasion in surgically treated esophageal squamous cell carcinoma.手术治疗食管鳞癌中神经周围侵犯的预后影响。
Thorac Cancer. 2021 May;12(10):1605-1612. doi: 10.1111/1759-7714.13960. Epub 2021 Apr 3.
8
FOXO1 promotes tumor progression by increased M2 macrophage infiltration in esophageal squamous cell carcinoma.FOXO1 通过增加食管鳞状细胞癌中的 M2 巨噬细胞浸润促进肿瘤进展。
Theranostics. 2020 Sep 16;10(25):11535-11548. doi: 10.7150/thno.45261. eCollection 2020.
9
HIPK3 Promotes Growth and Metastasis of Esophageal Squamous Cell Carcinoma via Regulation of miR-599/c-MYC Axis.HIPK3通过调控miR-599/c-MYC轴促进食管鳞状细胞癌的生长和转移。
Onco Targets Ther. 2020 Mar 6;13:1967-1978. doi: 10.2147/OTT.S217087. eCollection 2020.
10
Tumor Compactness based on CT to predict prognosis after multimodal treatment for esophageal squamous cell carcinoma.基于 CT 的肿瘤密实度预测食管鳞癌多模态治疗后的预后。
Sci Rep. 2019 Jul 19;9(1):10497. doi: 10.1038/s41598-019-46899-x.

本文引用的文献

1
Preoperative chemoradiotherapy for esophageal or junctional cancer.术前放化疗治疗食管或食管胃交界癌。
N Engl J Med. 2012 May 31;366(22):2074-84. doi: 10.1056/NEJMoa1112088.
2
Worldwide esophageal cancer collaboration.全球食管癌协作组织
Dis Esophagus. 2009;22(1):1-8. doi: 10.1111/j.1442-2050.2008.00901.x.
3
Comparison of 7 staging systems for patients with hepatocellular carcinoma undergoing transarterial chemoembolization.接受经动脉化疗栓塞术的肝细胞癌患者的7种分期系统比较。
Cancer. 2008 Jan 15;112(2):352-61. doi: 10.1002/cncr.23185.
4
Therapeutic strategies in oesophageal carcinoma: role of surgery and other modalities.食管癌的治疗策略:手术及其他治疗方式的作用
Lancet Oncol. 2007 Jun;8(6):545-53. doi: 10.1016/S1470-2045(07)70172-9.
5
Validation of clinical AJCC/UICC TNM staging system for hepatocellular carcinoma: analysis of 5,613 cases from a medical center in southern Taiwan.肝细胞癌临床AJCC/UICC TNM分期系统的验证:来自台湾南部一家医学中心的5613例病例分析。
Int J Cancer. 2007 Jun 15;120(12):2650-5. doi: 10.1002/ijc.22616.
6
American Joint Committee on Cancer staging system does not accurately predict survival in patients receiving multimodality therapy for esophageal adenocarcinoma.美国癌症联合委员会分期系统不能准确预测接受多模式治疗的食管腺癌患者的生存率。
J Clin Oncol. 2007 Feb 10;25(5):507-12. doi: 10.1200/JCO.2006.08.0101.
7
The number of lymph nodes with metastasis predicts survival in patients with esophageal or esophagogastric junction adenocarcinoma who receive preoperative chemoradiation.发生转移的淋巴结数量可预测接受术前放化疗的食管或食管胃交界腺癌患者的生存率。
Cancer. 2006 Mar 1;106(5):1017-25. doi: 10.1002/cncr.21693.
8
Posttherapy pathologic stage predicts survival in patients with esophageal carcinoma receiving preoperative chemoradiation.治疗后病理分期可预测接受术前放化疗的食管癌患者的生存情况。
Cancer. 2005 Apr 1;103(7):1347-55. doi: 10.1002/cncr.20916.
9
Preoperative chemoradiotherapy for oesophageal cancer: a systematic review and meta-analysis.食管癌术前放化疗:一项系统评价与荟萃分析
Gut. 2004 Jul;53(7):925-30. doi: 10.1136/gut.2003.025080.
10
Refining esophageal cancer staging.优化食管癌分期
J Thorac Cardiovasc Surg. 2003 May;125(5):1103-13. doi: 10.1067/mtc.2003.170.

术前放疗的食管鳞癌患者预后:不同癌症分期系统的比较。

Prognosis of esophageal squamous cell carcinoma patients with preoperative radiotherapy: Comparison of different cancer staging systems.

机构信息

Department of Radiation Oncology, Cancer Institute and Hospital, Chinese Academy of Medical Sciences Beijing, China.

Department of Pathology, Cancer Institute and Hospital, Chinese Academy of Medical Sciences Beijing, China.

出版信息

Thorac Cancer. 2014 May;5(3):204-10. doi: 10.1111/1759-7714.12079. Epub 2014 Apr 22.

DOI:10.1111/1759-7714.12079
PMID:26767002
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC4704300/
Abstract

BACKGROUND

The 7th edition American Joint Committee on Cancer tumor-node-metastasis (AJCC TNM) staging system was published in 2010. Here we evaluate its predictive ability and compare the 6th and 7th editions of the AJCC TNM staging systems in esophageal squamous cell cancer (ESCC) with preoperative radiotherapy.

METHODS

A total of 296 esophageal squamous cell carcinoma patients receiving preoperative radiotherapy between 1980 and 2007 were included. Patients were staged using the 6th and 7th edition staging systems. Survival analyses were performed using Cox regression models. The homogeneity, discriminatory ability, and monotonicity of gradients of the two staging systems were compared using linear trend χ(2), likelihood ratio statistics, and Akaike information criterion calculation.

RESULTS

The overall five-year survival rate for the entire cohort was 27.1%. Female gender, length, "T," and "N," classifications according to the 7th edition staging system were the prognostic factors in univariate analyses. However, tumor histological grade and cancer location did not significantly influence patient survival. The 7th edition staging system has the highest linear trend χ(2)and likelihood ratio χ(2)scores. Compared to the 6th edition, the 7th edition staging system also has a smaller Akaike information criterion value, which represents the optimum prognostic stratification.

CONCLUSIONS

The strength of the 7th edition AJCC TNM staging system lies in the new descriptors for "T" and "N" classifications. However, we did not find cancer location to be a significant prognostic factor in our cohort. Overall, the 7th edition AJCC TNM staging system performed better than the previous edition.

摘要

背景

2010 年发布了第 7 版美国癌症联合委员会肿瘤-淋巴结-转移(AJCC TNM)分期系统。在此,我们评估其预测能力,并将食管鳞癌(ESCC)术前放疗的第 6 版和第 7 版 AJCC TNM 分期系统进行比较。

方法

共纳入 1980 年至 2007 年间接受术前放疗的 296 例食管鳞癌患者。采用第 6 版和第 7 版分期系统对患者进行分期。采用 Cox 回归模型进行生存分析。通过线性趋势 χ(2)、似然比统计和 Akaike 信息准则计算,比较两种分期系统的同质性、区分能力和梯度单调性。

结果

全队列的总五年生存率为 27.1%。女性性别、长度、第 7 版分期系统的“T”和“N”分类是单因素分析中的预后因素。然而,肿瘤组织学分级和癌症位置对患者生存没有显著影响。第 7 版分期系统具有最高的线性趋势 χ(2)和似然比 χ(2)评分。与第 6 版相比,第 7 版分期系统的 Akaike 信息准则值更小,代表了最佳的预后分层。

结论

第 7 版 AJCC TNM 分期系统的优势在于“T”和“N”分类的新描述符。然而,我们在本队列中未发现癌症位置是一个显著的预后因素。总体而言,第 7 版 AJCC TNM 分期系统优于前一版。